85 related articles for article (PubMed ID: 23884369)
1. Breast cancer stem cells--ready for their close-up?
Calhoun KE
JAMA Surg; 2013 Sep; 148(9):878. PubMed ID: 23884369
[No Abstract] [Full Text] [Related]
2. Breast cancer: Mutations in breast cancer stem cells correlate with metastases.
Marchesi V
Nat Rev Clin Oncol; 2013 Oct; 10(10):546. PubMed ID: 23939549
[No Abstract] [Full Text] [Related]
3. Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Donovan CA; Pommier RF; Schillace R; O'Neill S; Muller P; Alabran JL; Hansen JE; Murphy JA; Naik AM; Vetto JT; Pommier SJ
JAMA Surg; 2013 Sep; 148(9):873-8. PubMed ID: 23884447
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
6. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?
Mayer IA; Arteaga CL
J Clin Oncol; 2014 Sep; 32(27):2932-4. PubMed ID: 25071103
[No Abstract] [Full Text] [Related]
8. Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Shalmon B; Drendel M; Wolf M; Hirshberg A; Cohen Y
Int J Oral Maxillofac Surg; 2016 Jun; 45(6):721-5. PubMed ID: 26811072
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of women with early breast cancer and PIK3CA mutations.
Di Cosimo S; Bianchi GV; Bregni G; de Braud F
Breast; 2015 Jun; 24(3):283-4. PubMed ID: 25772325
[No Abstract] [Full Text] [Related]
10. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
11. The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma.
Li XC; Liu C; Huang T; Zhong Y
Biomed Res Int; 2016; 2016():5237827. PubMed ID: 27190992
[TBL] [Abstract][Full Text] [Related]
12. Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.
Juric D; Baselga J
J Clin Oncol; 2012 Mar; 30(8):765-6. PubMed ID: 22271482
[No Abstract] [Full Text] [Related]
13. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.
Volckmar AL; Leichsenring J; Flechtenmacher C; Pfarr N; Siebolts U; Kirchner M; Budczies J; Bockmayr M; Ridinger K; Lorenz K; Herpel E; Noske A; Weichert W; Klauschen F; Schirmacher P; Penzel R; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2017 Jan; 56(1):11-17. PubMed ID: 27438523
[TBL] [Abstract][Full Text] [Related]
14. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Boyault S; Drouet Y; Navarro C; Bachelot T; Lasset C; Treilleux I; Tabone E; Puisieux A; Wang Q
Breast Cancer Res Treat; 2012 Feb; 132(1):29-39. PubMed ID: 21512767
[TBL] [Abstract][Full Text] [Related]
15. Rare occurrence of EGFR exon 19 deletion in invasive lobular carcinoma of the breast.
Moatamed NA; DeNicola M; Nham P; Phan RT
Breast J; 2018 May; 24(3):429-431. PubMed ID: 29139619
[No Abstract] [Full Text] [Related]
16. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer: not a borderline issue!
Birrer MJ
Cancer Biol Ther; 2006 Jul; 5(7):786-7. PubMed ID: 16921259
[No Abstract] [Full Text] [Related]
18. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
Datta D; Flaxenburg JA; Laxmanan S; Geehan C; Grimm M; Waaga-Gasser AM; Briscoe DM; Pal S
Cancer Res; 2006 Oct; 66(19):9509-18. PubMed ID: 17018607
[TBL] [Abstract][Full Text] [Related]
19. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
